TEVA-QUETIAPINE XR TABLET (EXTENDED-RELEASE)

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

QUETIAPINE (QUETIAPINE FUMARATE)

Tilgjengelig fra:

TEVA CANADA LIMITED

ATC-kode:

N05AH04

INN (International Name):

QUETIAPINE

Dosering :

300MG

Legemiddelform:

TABLET (EXTENDED-RELEASE)

Sammensetning:

QUETIAPINE (QUETIAPINE FUMARATE) 300MG

Administreringsrute:

ORAL

Enheter i pakken:

15G/50G

Resept typen:

Prescription

Terapeutisk område:

ATYPICAL ANTIPSYCHOTICS

Produkt oppsummering:

Active ingredient group (AIG) number: 0131858005; AHFS:

Autorisasjon status:

APPROVED

Autorisasjon dato:

2013-03-08

Preparatomtale

_ _
_Teva-Quetiapine XR Tablets_
_ _
_Page 1 of 93_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
TEVA-QUETIAPINE XR
Quetiapine Fumarate Extended-Release Tablets
Tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg quetiapine (as
quetiapine fumarate), Oral
Teva Standard
Antipsychotic / Antidepressant Agent
Teva Canada Limited
30 Novopharm Court
Toronto, ON
M1B 2K9
Canada
www.tevacanada.com
Date of Initial Authorization:
March 08, 2013
Date of Revision:
August 25, 2022
Submission Control No: 262415
_ _
_Teva-Quetiapine XR Tablets_
_ _
_Page 2 of 93_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS - Musculoskeletal - Rhabdomyolysis
08/2022
7 WARNINGS AND PRECAUTIONS - Psychiatric
08/2022
7 Warnings and Precautions - Skin
08/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................ 4
1.
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
5
1.2
Geriatrics
...................................................................................................................
5
2.
CONTRAINDICATIONS
.................................................................................................
5
3.
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................. 5
4.
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1
Dosing Considerations
...............................................................